BioCentury
ARTICLE | Clinical News

Sunesis starts Ph Ib/II of SNS-062 for B cell malignancies

August 4, 2017 7:51 PM UTC

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) began an open-label, U.S. Phase Ib/II trial of SNS-062 to treat chronic lymphocytic leukemia (CLL), small lymphocytic leukemia, Waldenstrom’s macroglobulinemia and mantle cell lymphoma (MCL) in up to 124 patients who progressed after prior therapy, including a Bruton's tyrosine kinase (Btk) inhibitor.

Patients will receive twice-daily 25, 50, 100, 200, 300, 400 or 500 mg oral SNS-062 in Phase Ib. The Phase Ib portion will determine the Phase II dose. Phase II will include a cohort of relapsed CLL patients with the Btk C481s mutation...